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Abstract. Fluorescent proteins and dyes are routine tools for biological research to describe the behavior of
genes, proteins, and cells, as well as more complex physiological dynamics such as vessel permeability
and pharmacokinetics. The use of these probes in whole body in vivo imaging would allow extending the
range and scope of current biomedical applications and would be of great interest. In order to comply with
a wide variety of application demands, in vivo imaging platform requirements span from wide spectral coverage
to precise quantification capabilities. Fluorescence molecular tomography (FMT) detects and reconstructs in
three dimensions the distribution of a fluorophore in vivo. Noncontact FMT allows fast scanning of an excitation
source and noninvasive measurement of emitted fluorescent light using a virtual array detector operating in free
space. Here, a rigorous process is defined that fully characterizes the performance of a custom-built horizontal
noncontact FMT setup. Dynamic range, sensitivity, and quantitative accuracy across the visible spectrum
were evaluated using fluorophores with emissions between 520 and 660 nm. These results demonstrate
that high-performance quantitative three-dimensional visible light FMT allowed the detection of challenging
mesenteric lymph nodes in vivo and the comparison of spectrally distinct fluorescent reporters in cell culture.
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1 Introduction
In vivo optical imaging instruments have become mainstream
tools for the visualization of molecular function and disease
diagnostics. Fluorescence molecular tomography (FMT) offers
an advantage over other optical imaging techniques in its ability
to accurately quantify fluorescent signal.1–3 Defining the perfor-
mance of fluorescence tomography imagers is of primary
importance because it is the ability to quantify fluorescent con-
centration that will spur the development of new biological
applications. In FMT technology, fluorescence provides contrast
between targeted and nontargeted tissues noninvasively4 using
noncontact detectors.5–7 For a sample of given optical properties,
the emitted intensity is dependent on the distance between the
source and the fluorescent object8 and on the intensity of the
excitation beam.9–11 Tomographic information is obtained at
multiple projections, and the variation in fluorescence intensity
at each projection is used to extrapolate spatial information.12–14
FMT image reconstruction computes the concentration of a flu-
orophore and its volume, making some assumptions about its
absorption and scattering coefficients,15,16 knowing the sample
thickness,17 and experimentally measuring the normalized Born
approximation18 to retrieve the position, shape, and concentra-
tion of a target fluorophore.19 A three-dimensional (3-D) image
is generated by creating a weight matrix of the sample, where
voxel intensity values are assigned iteratively.15,20–22 However,
in biological research, measuring fluorescence is effectively
performed in a semiquantitative manner, and it is necessary
for the user to define an “application-tailored” signal-to-noise
ratio (SNR) and choose fluorophores based on the properties of
the imager. From the user’s perspective, fluorescence emission
intensity depends on the following variables: excitation inten-
sity,23 spectral characteristics of the target fluorophore,2,24
spectral properties of the tissue sampled,25 and bandpass filters
used; and it is ultimately proportional to fluorophore concentra-
tion. It follows that if the variable parameters can be controlled,
emission can be measured consistently and the diffusion
approximation11,22 solved for fluorophore concentration. As
the major absorber of visible light in living organisms, hemo-
globin plays a crucial role in light transmission and imaging
gene activity effectively in vivo, beyond 600 nm is highly
desirable; however, the number of applications using NIR fluo-
rescent proteins is still small. The need to evaluate true in vivo
*Address all correspondence to: Rosy Favicchio, E-mail: r.favicchio@imperial
.ac.uk
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performance of fluorescent proteins (FPs) within the visible
spectral window is thereby crucial, given that the choice of
unsuitable reporter fluorophores could lead to inaccurate results
independent of FMT imager performance.
Here, the capabilities and limitations of a custom-built non-
contact FMT system in localizing and quantifying fluorescent
signal under variable experimental conditions were evaluated
in vitro, in cell culture, and in vivo. To this purpose, we made
use of a Tet-ON conditional gene expression system26 where
five FPs were cloned in stable cell lines within the same genetic
locus, thus resulting in identical mRNA expression levels.
Since promoter activity was equal, it follows that variability
in fluorescence emission intensity could be directly related to
the activity of each FP (including brightness, stability, cell tox-
icity, and so on). In vivo validation of the FMT detection sensi-
tivity was tested by targeting subcutaneous and deep-seated
lymph nodes (LNs) in a transgenic mouse model. The FMT
was used to quantify the T-cell population,27 focusing on how
to overcome the practical challenges of detecting fluorescence
from different anatomical locations. These data provide essential
information for application design by establishing the quantita-
tive accuracy, standardization, and reproducibility of the FMT
imager. A calibration method was further established that
enabled conversion of FMT signal intensity to molarity. In con-
clusion, these data describe a set of methodological steps that
validate noncontact free-space fluorescence tomography in vitro
and in vivo as an accurate technique for the detection and quan-
titative comparison of spectrally distinct fluorophores emitting
between 520 and 660 nm.
2 Materials and Methods
2.1 Experimental Setup
The experimental noncontact FMT setup used [Fig. 1(a)]
employed a continuous-wave argon-ion laser source
(LaserPhysics, Reliant 1000m, West Jordan, Utah) emitting at
457, 488, and 514 nm and enclosed in a custom-built aluminum
chamber coated in antireflective black coating (deep black opti-
cal paint, Gerd Neumann, Hamburg, Germany). The source was
directed across three fixed mirrors (High Energy Argon-Ion
Laser Mirrors, Edmund Optics, Barrington, Illinois) and a
UV–NIR neutral density filter (Edmund Optics) into the FMT
chamber and onto an optical scanner employing galvo-mirrors
(Scanlab, SCANcube 7, Munich, Germany). Incident light
power was measured before entering the optical scanner using
a laser power meter (PH100-Si-OD2, Gentec Electro-Optics).
The setup was designed to operate in both transmission and
reflection geometries by repositioning a mirror (First Surface
mirror, Edmund Optics) mounted on a travel linear translation
stage (Edmund Optics). The sample holder was mounted on an
electronically controlled x − y − z positioning stage (Standa,
Vilnius, Lithuania). A custom-built filter wheel accommodating
up to five filters was aligned to a 50 mm Macro f∕2.8 objective
(SIGMA Corporation, Tokyo, Japan). Light collection was per-
formed using a 510∕10-, 540∕40-, 593∕40-, or 615∕90-nm
interference bandpass filters (Andover Corporation, Salem,
New Hampshire) to isolate fluorescence from excitation light.
A 16-bit, 1024 × 1024 pixel charge-coupled device (CCD)
(DV 434, Andor Technology, Belfast, Northern Ireland),
thermoelectrically cooled down to −65°C, was used for the
detection of signals. The lens was focused on the surface of
the sample, and the image scaled from pixel dimensions to
metric units by the use of metric fiducials. Stage calibration
was performed to convert the CCD field of view to degrees of
rotation of the galvo-mirrors. For all experiments, an image was
obtained with white light illumination before exposure to the
laser source and was used as a reference image for source pattern
selection. Additionally, a background image in the absence of an
illuminating source was acquired to account for any external
light entering the FMT chamber. Illumination sources were dis-
tributed symmetrically to the target location for both reproduc-
ibility and calibration experiments. Exposure time used was
0.2 s with 0.8 mW excitation power. Identical source/detector
parameters were used for the fluorophores Atto590 (excitation
max 594 nm, emission max 624 nm; ATTO-TEC Gmbh,
Germany) and carboxyfluorescein succidimyl ester (CFSE)
(excitation max 492 nm, emission max 517 nm; Thermo Fisher
Scientific Inc.) placed in a 2-mm capillary glass tube in a phan-
tom at a depth of 3 mm from the surface. A slab geometry phan-
tom was used with a combination of 20 ppm India ink and
1% Intralipid-20% to match tissue-like optical properties at
520 nm (scattering coefficient μs ¼ 16 cm−1 and absorption
coefficient μa ¼ 0.3 cm−1) and at a depth of 12 mm. An isoflur-
ane vaporizer was used to deliver anesthetic to the FMT cham-
ber and to the induction chamber, and a scavenging system
was used to remove excess anesthetic gas (Fluovac systems,
Harvard Apparatus, Hollison, Massachusetts).
2.2 Tomographic Data Acquisition and
Reconstruction
Tomographic imaging was performed by scanning the laser
source into selected illumination points.23 The optimum excita-
tion source pattern found for the tomographic scans was an 8 × 8
grid covering a field of view of 12 × 12 mm. For each illumi-
nation point, two measurements (excitation and emission) were
recorded sequentially with the appropriate bandpass filters
placed in front of the CCD. An image stack was created for
all illumination points creating two sets of raw data (excitation
and emission). Excitation and emission stacks were then
resampled to a 14 × 14 detector grid covering the target area
and used for the tomographic reconstructions. Data from the
excitation and emission stacks were used to create the normal-
ized Born ratio18 as shown in the following equation:
EQ-TARGET;temp:intralink-;e001;326;293UnB ¼ Ufl
Uexc
¼ Wfl · fluoðrÞ; (1)
where UnB is the normalized measurement, Ufl and Uexc are the
background corrected fluorescence and excitation measure-
ments, Wfl is the weight matrix describing the light propagation
through the specific medium, and fluoðrÞ is the fluorescence
concentration. The 3-D reconstruction [Figs. 1(b)–1(e)] was per-
formed using diffusion theory and modeling light propagation16
in free space5 in a homogenous slab solution.8,19 The tissue
medium below the detector area was discretized to a total of
2700 voxels of 1 mm × 1 mm × 1 mm centered to the target
area. Data inversion was performed using an iterative
approach,20,21,28 and 3-D reconstructions were obtained with
100 iterations (Table 1). For phantom experiments, a cylindrical
region of interest (ROI) was selected and the mean intensity
value was used for quantification. Variation of the number of
iterations did not affect the ROI mean. The source/detector pat-
terns used in transmission geometry were identical to those in
reflection modality (10 mW excitation power and 2 s exposure
3
Fig. 1 Horizontal noncontact FMT imaging system. (a) The FMT setup is illustrated, where the argon-ion
source directs the beam into the FMT chamber via two fixed mirrors and into a scan cube that directs the
beam via galvo-mirrors onto different user-selected source positions on the sample. The laser source can
be directed onto the sample in reflection or transmission geometry by the use of a sliding mirror. Light is
collected by a CCD camera, where wavelength is selected by the use of bandpass filters placed on a filter
wheel. The data are recorded by a PC. The FMT imager was used to image a phantom containing a glass
capillary tube filled with 10-μMCFSE. (b) 3-D reconstructed image of the capillary tube was obtained with
100 iterations; the tube was clearly visible and geometrically correctly reconstructed. (c) The x − y plane
showed the reconstructed tube in line with its true location, visible in the background image, and 2 mm
below the surface. (d) The y − z plane and (e) x − z plane images demonstrated that the FMT software
correctly reconstructed the tube as a cylindrical object with a homogeneous fluorescent signal.
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time). Data acquisition and processing were performed on a
3.0 GHz Pentium D with 512 MB RAM, and the system was
controlled by custom-built software using LabView (National
Instruments, Austin, Texas) system design software.
2.3 Fluorescence Molecular Tomography
Calibration
Fluorophore quantum yield (QY) defines the efficiency with
which absorbed light is converted to emitted light. Published
QYs, however, are recorded at excitation and emission maxima.
Such conditions often fail to match experimental conditions due
to the wavelengths available and also because experimentally
the QY is affected by concentration range and solvent properties.
Commercial QY values therefore could not be used for FMT
imaging calibration; we used the linear quantification data
from CFSE and Atto590 to calculate the FMT-fluorescence
yield (FMT-FY) described for our samples and experimental
parameters. A plot of FMT-recorded intensities (F) (y-axis)
against measured sample absorbance A (x-axis) (FluoroMax,
Jobin Yvon, Horiba Scientific, Kyoto, Japan) was obtained
by multiplying the known fluorophore concentrations (c) by
their published extinction coefficient values (ε) and measured
light path length (l) following Beer–Lambert’s law:
EQ-TARGET;temp:intralink-;e002;63;244 ¼ ε · c · l: (2)
For CFSE, ε488 ¼ 59;668.
For Atto590, ε514 ¼ 12;000.
The absorbance values were then plotted and fitted to a linear
regression model, as shown in Fig. 2. The slope of the fits (m) is
proportional to the QY of the fluorophore, where b is the inter-
cept on the y-axis:
For CFSE, m ¼ 1.27 × 10−8, b ¼ 0; and
For Atto590, m ¼ 2.25 × 10−8, b ¼ 9.50 × 10−4.
FMT-FY values were calculated using a standard (st) solu-
tion as reference; FMT-FYx is thus always expressed as relative
to FMT-FYst as follows:
EQ-TARGET;temp:intralink-;e003;326;502ϕx ¼ ϕst

mx
mst

η2x
η2st

; (3)
where ϕ is the FMT-FY of, relatively, the sample (ϕx) and the
standard (ϕst), and η is the refractive index of the solvent. We
calculated the FMT-FY for CFSE (ϕCFSE) and Atto590 (ϕAtto)
using the published QY values as ϕst, corrected for the wave-
lengths used:
For CFSE, ϕmax ¼ 0.80, ϕ488;540 ¼ 0.40; and
For Atto590, ϕmax ¼ 0.80, ϕ514;615 ¼ 0.08.
The calculated FMT-FY for CFSE and Atto590 was
EQ-TARGET;temp:intralink-;sec2.3;326;359ϕCFSE ¼ 0.45; ϕAtto590 ¼ 0.70:
The ratio of the calculated FMT-FYs (ϕ) was then compared
with the ratio between the slopes (m):
EQ-TARGET;temp:intralink-;sec2.3;326;306
ϕCFSE
ϕAtto
¼ 0.45
0.70
¼ 0.635;
mCFSE
mAtto
¼ 1.27e
−8
2.25e−8
¼ 0.563;
ϕAtto
ϕCFSE
¼ 0.70
0.45
¼ 0.157;
mAtto
mCFSE
¼ 2.25e
−8
1.27e−8
¼ 0.177:
The calculated slopes were proportional to the FMT-FYs and
consequently to the fluorophores’ QYs (within 10% error). The
linear relationship between fluorescence emission intensity and
concentration [Eq. (4)] therefore becomes:
EQ-TARGET;temp:intralink-;e004;326;139F ¼ m  ε  cþ b; (4)
where F is the fluorescence emission intensity detected by the
FMT, m is the slope of the fit, and b is the intercept of the linear
fit. The slope of each fit (m), specific for each fluorophore (ε),
could therefore be used as a “calibration factor” for the FMT
Table 1 Comparative statistical analysis for quantification experiments in reflection (R) and transmission (T) modalities. Phantoms with increasing
concentrations of CFSE and Atto590 were imaged with the FMT and emission quantified for each dataset. The correlation between the linear
regressionmodel used and the experimental data points is illustrated by theR2 and SDM values. The slope values were used asmeans to compare
reproducibility between modalities. Increasing the number of iterations from 100 to 1000 marginally improves the fits (bold) and the slope. Small
differences in slope values can be noticed between reflection and transmission experiments, indicating that a quantitative comparison of values
between modalities is possible but may be affected by the intensity range.
Fluorophore Mode Iterations R2 SDM N Slope
CFSE R 100 0.99811 1.01172 × 10−4 4 5.1966 × 10−4
CFSE R 1000 0.99981 3.8746 × 10−5 4 6.3025 × 10−4
CFSE T 100 0.98518 4.06563 × 10−4 4 7.41105 × 10−4
CFSE T 1000 0.98463 4.39479 × 10−4 4 7.8644 × 10−4
Atto590 R 100 0.97909 2.5702 × 10−4 4 2.22456 × 10−4
Atto590 R 1000 0.98412 1.89737 × 10−4 4 2.32 × 10−4
Atto590 T 100 0.99628 1.08321 × 10−4 4 2.2411 × 10−4
Atto590 T 1000 0.99738 1.02355 × 10−4 4 2.52562 × 10−4
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system. Dividing the FMT recorded intensities by (m  ε) recov-
ered the FMT concentration values. The details are provided in
Table 2.
2.4 Cell Culture
Stable HeLa cell lines expressing enhanced yellow fluorescent
protein (EYFP), super green fluorescent protein (SGFP),
enhanced green fluorescent protein (EGFP), Katushka,29 or
Cardinal30 red fluorescent protein were generated and character-
ized as described by Weidenfeld et al.26 In brief, HeLa Tet-ON
advanced cells (line EM2-11ht) were stably transfected with
DNA coding for the fluorescent proteins under control of a
tetracycline/doxycycline inducible promoter (Ptet). The
gene of interest was stably integrated into a defined genomic
locus (5q31), which allows tight regulation of the doxycy-
cline-inducible expression. Constructs were inserted by
Flippase Recombinase-Mediated Cassette Exchange (Flp-
RMCE), and clonal lines were isolated. The expression charac-
teristics of the derived cell lines were directly comparable as
the transgenes were directionally integrated as single copies
at the same locus. HeLa cells were cultured in DMEM supple-
mented with 10% FBS, 2 mM glutamine, and 1% penicillin/
streptomycin. Expression of SGFP, EGFP, EYFP, Katushka,
or Cardinal was induced by doxycycline, supplied to the
media at 200 ng∕ml. For FMT imaging of HeLa monolayers,
24-well tissue culture plates were used.
2.5 Animals
Rag1−/−,31,32 CD2,33 and DsRed34 transgenic animals were main-
tained in the Institute of Molecular Biology and Biotechnology
colony. For the FMT imaging, the animals (n ¼ 4) were anes-
thetized with 1.5% isoflurane, initially delivered at 2.5% in a tran-
quilizing chamber. Temperature and breathing of each animal
were monitored during the experimental procedure. Mesenteric
nodes (MNs) were detected after feeding the mice for 2 weeks
with alfalfa-free food (Labdiet), and hair was removed using
depilatory cream. All animal experimental protocols were con-
ducted in accordance with and under the approval of the
Foundation for Research and Technology Ethics Committee
and the General Directorate of Veterinary Services, Region
Crete (permit numbers: EL 91BIO-02 and EL91-BIOexp-02).
2.6 Cell Culture Experimental Protocol
A 24-well cell culture plate containing HeLa-wt and stable HeLa
clones expressing either EGFP, EYFP, SGFP, Katushka, or
Cardinal (n ¼ 3) was imaged using a two-dimensional (2-D)
raster scan, ensuring homogeneous excitation across samples.
The EGFP-, SGFP-, and EYFP-positive cells were excited using
the 488-nm laser line, and emission was recorded with
510∕10-nm and a 540∕40-nm filters. Katushka- and Cardinal-
positive cells were excited with the 514-nm laser line, and
593∕40-nm and 615∕90-nm filters were used for emission.
SGFP-positive cells were measured with all filter sets. To
mimic the high absorbance, freshly heparinated mouse blood
was added to the culture wells to a final concentration of 12%
(assuming a molar extinction coefficient of 24202.4
[cm−1∕ðmoles∕LÞ] at 520 nm, matching μa ¼ 16 cm−1). ROI
Fig. 2 FMT calibration. FMT-FY was calculated by converting CFSE and Atto590 concentrations
into absorbance values. FMT intensity values were plotted against measured absorbance value
(A ¼ ε  c  l) for four concentrations of (a) CFSE and (b) Atto590. The points were fitted to a linear
regression model, and the slope and intercept points were used to calculate the relative FMT-FY value.
Table 2 Conversion table. The molar concentrations of CFSE and
Atto590 used and the intensity values (a.u.) recovered from the
3D-FMT data analysis are shown. FMT concentration values re-
present the converted a.u. units to molarity obtained by the FMT cal-
ibration step.
FMT intensity FMT concentration
CFSE concentration (μM)
2 0.00165 2.18
4 0.00261 3.45
8 0.00575 7.60
10 0.00795 10.50
Atto590 concentration (μM)
5 0.00135 5.00
10 0.00275 10.18
15 0.00395 14.62
20 0.00545 20.18
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areas (identical for all samples) corresponding to the width of the
wells were used to quantify FP emission. The data were normal-
ized for filter width, excitation, and emission wavelength and for
cell number. Fluorimeter data were experimentally measured for
each population at 1 × 106 cells∕mL.
2.7 In Vivo Experimental Protocol
Initially, a 2-D scan was performed on each animal to locate the
target LN using 514-nm excitation and 615∕90-nm emission
(1 mW excitation power and 6 s exposure time). These images
were used to determine the scan pattern position: a 10 × 10
source grid was chosen to cover a wide field of view (2 × 2 cm)
with 25 mW excitation power and 0.2- to 0.6-s exposure time
for the superficial and deep targets, respectively. Tomographic
data were recorded using 514-nm excitation with 615∕90-nm
and a 690∕30-nm emission filters for fluorescence measurement
and a 510∕10-nm filter to measure the excitation field. The data
were processed with in-house developed software using a 10 ×
10 detector pattern.
3 Results
3.1 In Vitro Quantification
In order to assess the capabilities of the FMT system, a set of
experiments was designed to address its sensitivity, dynamic
range, and resolution. Each query was dependent on the SNR
and was therefore application dependent. Given that the optical
properties of the fluorescent object of interest and its immediate
surroundings significantly affected the SNR, each experiment
here reported was acquired using settings where the SNR was
experimentally maximized. A typical 3-D-reconstructed image
is shown in Fig. 1. The FMT imager was tested in reflection and
transmission geometry modes at different wavelengths. Initially,
response was assessed with phantoms containing 2, 4, 8, and
10 μM of CFSE in reflection geometry. To compare the quan-
tification accuracy at different spectral regions, CFSE was
replaced with Atto590. Atto590 has a high molecular absorption
and a high QY (0.80); however, the 514-nm source achieved
approximately 10% excitation efficiency. This resulted in a
60% weaker Atto590 emission compared with CFSE (excitation
max 489 nm). Atto590 concentrations (5, 10, 15, and 20 μM)
were chosen to match the intensity range used for CFSE.
Similarly, a set of experiments assessed the quantification
capabilities of the FMT imager in transmission geometry.
Quantification of mean intensity values in transmission geom-
etry was achieved using the same reconstruction and ROI
parameters used for reflection and were therefore directly com-
parable. The results from the quantification analysis for CFSE
and Atto590 in reflection and transmission modes (Fig. 3) were
fitted to a linear regression model (Table 1). The quantification
data showed the reconstructed fluorescence mean intensity val-
ues to be linearly proportional to fluorescence concentration.
3.2 In Vitro Reproducibility
The FMT imager’s reproducibility was then assessed by
designing a set of in vitro experiments carried out in reflection
geometry using 2-μM CFSE. Data acquisition, processing, ROI
selection, and quantification were obtained (excitation 488 nm,
emission 540∕40 nm; 8 × 8 source/detector pattern, 100 itera-
tions) for four independent measurements performed as technical
repeats. Reproducibility was assessed by standard deviation of the
mean (SDM) and standard error of the mean (SEM), 1.61334 ×
10−5 and 8.0667 × 10−6, respectively, 2 and 3 orders of magnitude
smaller than the mean (0.00204 a.u.), with a coefficient of variance
of 0.00792 indicating a systemic error <0.8%. Conversion using
the calibration factor in Eq. (4) recovered a value of 2.69 μM.
3.3 Optimal Fluorescent Protein Selection for
Fluorescence Molecular Tomography
The intrinsic properties of fluorescent proteins dictate whether
or not they are suitable for an application; however, these are
seldom explicitly tested. The relative intensities of the emission
displayed by identical numbers of HeLa cells expressing YFP,
SGFP, EGFP, Katushka, or Cardinal were obtained by quantify-
ing the mean FMT reconstructed values. The mean intensity val-
ues recorded [Figs. 4(a) and 4(b)] were corrected for filter width.
These normalized data give a more accurate intensity value for
each fluorophore considered; more precisely, they represent a
weighted average across the filter wavelength range.
Fig. 3 Quantification of FMT fluorescent signal in reflection and transmission modalities at different
wavelengths. Increasing concentrations of (a) CFSE and (b) Atto590 were measured; fluorescence
was detected using the FMT imager in reflection (black) and transmission (red) modalities. The mean
intensity values for each experiment were then plotted against the known concentration values and
fitted to a linear model. R2 > 0.98 for all fits (Table 1).
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For increased spectral resolution, a dedicated spectral
imager2 would be required. Green emitters were approximately
1 order of magnitude brighter than red emitters. The data were
further corrected for the “excitation efficiency” term achieved
by the available laser lines (488 and 515 nm). To address the
nonlinear relationship between excitation wavelength and emis-
sion intensity, the values were corrected by an experimentally
defined “efficiency factor” as follows:
EQ-TARGET;temp:intralink-;e005;63;191I½Greensex 488 × ðI½exmax∕I½ex488Þ (5)
and
EQ-TARGET;temp:intralink-;e006;63;149I½Redsex 515 × ðI½exmax∕I½ex515Þ: (6)
Exmax, ex488, and ex515 intensity values were obtained using
a fluorimeter, where spectral data were measured using each cell
line. Figure 4 shows how, even by exciting at the excitation
peak, red emitters still display weak emission and GFP emission
is still clearly detectable using a >600-nm filter. The data were
then corrected for the “emission efficiency” achieved: the emis-
sion spectral profiles obtained for the cells were used to calcu-
late the integrals for the whole emission curve and, separately,
the integrals for the wavelengths covered by each filter used to
image the sample with the FMT as follows:
• 510-nm filter: 505 nm → 515 nm;
• 540-nm filter: 520 nm → 560 nm;
• 593-nm filter: 573 nm → 613 nm; and
• 615-nm filter: 570 nm → 660 nm.
The ratio of the “whole emission curve”/“detected emission”
represents the portion of fluorescent signal actually detected by
the FMT:
EQ-TARGET;temp:intralink-;e007;326;120I½Greenscorrected×
Z
max
min
emicurve∕
Z
505
510
emicurve

; (7)
or
Fig. 4 Fluorescent protein emission comparison. A 24-well cell culture plate, each containing
1 × 106 cells expressing EGFP, SGFP, SYFP, Katushka, and Cardinal, was imaged using the FMT
imager with or without addition of 12% heparinated blood. Excitation was performed using 488-
and 514-nm laser lines, and fluorescence was recorded with 510∕10-, 540∕40-, 593∕40-, and
615∕90-nm filters. (a) Intensity values for each fluorophore were recorded with the optimal filter combi-
nation. The intensity values for red emitters are expanded in (b); SGFPRed indicates SGFP-expressing
cells detected with the red filter for comparative purposes. The intensity values were normalized to take
into account the fluorophore-specific excitation/emission efficiency. The measured normalized values
(Norm) and calculated potential values (Pot) are shown for the (c) green and (d) red channels.
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EQ-TARGET;temp:intralink-;e008;63;752I½Greenscorrected×
Z
max
min
emicurve∕
Z
560
520
emicurve

; (8)
or
EQ-TARGET;temp:intralink-;e009;63;706I½Redscorrected ×
Z
max
min
emicurve∕
Z
613
573
emicurve

; (9)
or
EQ-TARGET;temp:intralink-;e010;63;655I½Redscorrected ×
Z
max
min
emicurve∕
Z
660
570
emicurve

: (10)
The “corrected” values [Figs. 4(c) and 4(d), dashed lines]
represent the achievable values by exciting the fluorophores
at their excitation maximum and detecting the whole of the
emission curve. A final correction that could be made to
these values is defined by the QY. This correction should, in
theory, equalize the values for the different fluorophores at
identical concentrations. Unfortunately, QY information for the
specific fluorescent proteins used here was unavailable at the
time of writing.
3.4 In Vivo Small Animal Imaging
LNs represent highly desirable targets for in vivo imaging due to
their functional importance to the immune system. An immune
response is in fact a localized process with LNs acting synerg-
istically while remaining independent from one another. To test
whether the FMT could resolve fluorescence from anatomically
diverse LNs, the inguinal and mesenteric LNs of a CD2/DsRed
mouse were targeted. The inguinal LN is located subcutaneously
at the height of the groin, while the MNs are found bunched
(usually five to six nodes) deep within the mesentery of the
intestine. Figure 5 shows the raw fluorescence data (a) and
the 3-D reconstructed image (b) for the right inguinal LN of
a CD2/DsRed mouse. The FMT software correctly located the
origin of the fluorescent signal, and the reconstructed image
matched the dimensions and anatomical conformation of
the inguinal LN. The mesenteric LNs of a CD2/DsRed and
a nonfluorescent control mouse were then targeted (Fig. 6).
The morphology and location of the MNs make target recogni-
tion a difficult task; however, the DsRed-positive reconstructed
image displayed three times as much fluorescent signal than
the control sample. The bright autofluorescent object visible in
both the control and DsRed animals was identified ex vivo as
the gallbladder. The DsRed signal located at 0.5 to 1 cm below
the gallbladder is consistent with the MNs.
4 Discussion
The performance of a noncontact FMT system was demon-
strated by assessing its quantification accuracy and data repro-
ducibility within 520- to 660-nm windows of the visible
spectrum. These data reflect biologically valuable wavelengths,
given that most fluorescent proteins and dyes in current use
emit light within that range. These wavelengths are particularly
challenging for quantitative optical imaging setups, given that
the contribution of autofluorescence, scattering, and absorption
by biological tissues is nonlinear. It is useful to note that
although NIR fluorescent proteins and probes have been devel-
oped over the past decade, their use in biological applications is
still lagging compared with well-established green fluorescent
proteins such as GFP, and the use of many markers, including
fluorescently labeled antibodies, used in fluorescence micros-
copy has not been widely translated to an in vivo setting.
The nonlinear attenuation of light transmission in turn affects
the ability to compare fluorescence emissions from different
anatomical regions. In practice, this means that, in a typical
experimental design, fluorophores are compared with a control
sample group (e.g., before and after a treatment) and only rarely
to a spectrally distinct fluorophore. It is therefore important to
establish a method that enables the quantitative detection of
fluorescence, regardless of anatomical location and wavelength.
Reconstructed FMT intensities were here found to be linearly
dependent on fluorophore concentration, and this result was
reproduced irrespective of wavelength and acquisition geom-
etry, strengthening the notion that FMT can accurately retrieve
Fig. 5 Subcutaneous localization and FMT rendering of the inguinal LN of a CD2/DsRed mouse.
(a) Fluorescence tomography raw data (514 nm excitation; 615∕90 nm emission), and (b) FMT 3-D
reconstruction shows how the rendering process correctly localizes the shape and location of the LN.
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concentration values for subsurface and deeper-seated ROIs.
The reproducibility of the FMT data was evaluated by three
parameters: (1) the SNR was optimized experimentally to
reduce variance between background and target-specific emis-
sions; (2) SDM between FMT intensity and fluorophore concen-
tration was used as an indicator of dynamic range; and (3) SDM
of repeated measurements was used as an indicator of technical
accuracy. Standard deviation and standard error values through-
out this study were consistently found to be at least 1 to 2 orders
of magnitude smaller than the mean intensity value across inten-
sities. A protocol for the calibration of the FMT system was
established that allowed converting FMT intensity values to
fluorophore concentrations, with accuracy values that reflected
experimental variability. Repeated measurements were per-
formed, and the variance between measurements was found
to be 10−2 to 10−3 < mean. FMT quantification accuracy within
the visible spectrum was therefore in the nanomolar range and
formalized by the variance coefficient at <1%. The relative
strength of five fluorophores was evaluated in the presence of
blood in order to mimic the most challenging in vivo settings.
The absorption properties of the heme group around 500 nm
significantly affected the excitation light penetration. During
data processing, the normalization of excitation and emission
light resulted in an apparent increase of fluorescence in the pres-
ence of blood, dictated by a difference in absorbed excitation
light. It is clear from these data that FP performance should
be experimentally validated for each application and imaging
setup characteristic. Most red emitters were found to be approx-
imately 1 order of magnitude less bright than EGFP and EYFP;
therefore, in cases where excitation/emission excitation was
suboptimal, red FPs could be outperformed by green FPs.
The translational potential of these results to an in vivo setting
was demonstrated here by the detection and reconstruction of
fluorescently labeled T-cells in vivo. The FMT imager correctly
located two spectrally and anatomically distinct regions: the
inguinal LNs and the MNs of a transgenic CD2/DsRed mouse.
The quantification accuracy of the fluorescent reconstructions
in vivo was assessed separately using flow cytometry data.27
Cumulatively, the data demonstrate that noncontact FMT can
perform quantitative fluorescence imaging in vitro and in vivo
in a window of the visible spectrum with high precision and
provide the advantage of quantitatively comparing fluorescent
emissions across a wide spectral window, regardless of anatomi-
cal location.
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spread of fluorescent and autofluorescent objects. The area delimited by the red boxes represents
the area selected for the 3-D FMT rendering (b and d) for each mouse. The difference in anatomical
location of nontarget autofluorescent objects illustrates the challenges faced in the FMT reconstructions.
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